Salute e Benessere

Introducing FactsR™ by Corti -- the First Clinical Reasoning Layer for Ambient…

Unlike traditional LLM pipelines retrofitted for healthcare, FactsR is powered by Corti's recursive fact-first reasoning loop - a purpose-built engine designed to surface, validate, and structure clinical knowledge in real time as conversations unfold. Delivered as a modular API, it enables developers to embed clinical-grade intelligence directly into their healthcare applications - creating safer, leaner, and more trusted AI experiences at the point of care. Unlike traditional LLM pipelines...
PR Newswire
11/06/2025

Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover…

SOUTH SAN FRANCISCO, Calif., June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity. SOUTH SAN FRANCISCO, Calif. , June 11, 2025 /PRNewswire/ -- Deep Apple Therapeutics, Inc. announced today a research collaboration and...
PR Newswire
11/06/2025

Lembas Emerges from Stealth with Breakthrough Discovery in Natural GLP-1 for…

Nearly 75% of US adults are overweight or obese*, but the new GLP-1 pharmaceuticals are out of reach for many due to lack of accessibility, prohibitive costs, and severe side effects. This creates an urgent opportunity for the food and supplements industries to provide evidence-based solutions that help consumers manage their weight more naturally and effectively. Lembas is pioneering the next generation of science-backed bioactive ingredients for the functional food and supplements...
PR Newswire
11/06/2025

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File…

clinical trial supplies, has launchedNCE Grid, the world’s first freeNCE-1 intelligence platform- built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time.Until now, tracking NCE exclusivity expirations andParagraph IV filingshas been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using...
Nasdaq GlobeNewswire
11/06/2025

Kanazawa University research: High-speed AFM and 3D modelling help towards…

However, so far, it has been difficult to pin down information on the structural dynamics of ADAR1 due to its size and complexity. Now, researchers led by Madhu Biyani at Kanazawa University, WPI-NanoLSI, Yasuhiro Isogai at Toyama Prefectural University, and Manish Biyani at Ishikawa Create Labo and Kwansei Gakuin University have combined high-speed atomic force microscopy (HS-AFM) and 3D modelling to shed light on the enzyme's conformations and interactions with dsRNA. However, so far, it…
PR Newswire
11/06/2025

The Nomination Committee's proposal for Systemair's Annual General Meeting

The Nomination Committee proposes the re-election of Gerald Engström, Patrik Nolåker, Gunilla Spongh and Niklas Engström, as well as the election of two new members, Peter Fenkl and Åsa Söderström Winberg. Carina Andersson has declined re-election. Accordingly, the Committee proposes that the number of board members be increased by one, to a total of six. As announced on 7 April 2025, the Nomination Committee further proposes that Patrik Nolåker be elected Chairman of the Board and that Gerald…
PR Newswire
11/06/2025

Hansa Biopharma to attend BIO International Convention

Contacts for more information: Evan Ballantyne, Chief Financial OfficerIR@hansabiopharma.com Stephanie Kenney, VP Global Corporate Affairsmedia@hansabiopharma.com Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding...
PR Newswire
11/06/2025

Ascend Completes GMP Certification for Quality Control Testing in Munich…

ROCKVILLE, Md., June 11, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has received GMP certification for Quality Control (QC) testing at its site in Munich, Germany. ROCKVILLE, Md. , June 11, 2025 /PRNewswire/ --Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has received GMP certification for Quality Control (QC) testing at its site inMunich, Germany. "The team successfully completed a joint inspection by the...
PR Newswire
11/06/2025

London College of Contemporary Arts Launches Free Mental Health and Wellness…

"Many of our students are managing a range of personal, professional, and familial responsibilities while pursuing careers in creative industries, and media. Supporting their mental health is an investment not only in their personal welfare, but also in their long-term academic and career success," said Faye Mitcham, Interim Head of Student Accessibility Services at the London College of Contemporary Arts. "This partnership underscores our commitment to supporting the whole…
PR Newswire
11/06/2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007…

Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene that leads to progressive vision loss and blindness, with no approved treatments available. SB-007 is designed to address the underlying genetic cause of the disease by producing a functional copy of the full-length ABCA4 protein with the potential to treat all patients, regardless of their specific ABCA4 mutation. The proceeds will also be used to accelerate SpliceBio's pipeline of AAV gene therapy programs…
PR Newswire
11/06/2025

Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel…

Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disordersFirst-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs such as ketamineElkedonia, a new startup company launched by Argobio, attracts venture capital funding from a European syndicate of leading Life Sciences investorsElkedonia integrates research from Sorbonne...
Nasdaq GlobeNewswire
11/06/2025

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for…

Press releaseCROSSJECT advances on the development of ZEPIZURE®Junior, its solution for epilepsy crises in childrenAnnounces the effective calibration of ZENEO ®for the use of ZEPIZURE ®in the pediatric population.CROSSJECT completed an echography clinical study allowing to determine and validate the targeted depth of injection in children as compared to adults.Dijon, France 11 June 2025 (07h30 CET) -- CROSSJECT(ISIN: FR0011716265; Euronext: ALCJ), the specialty...
Nasdaq GlobeNewswire
11/06/2025

ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and…

The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver. To join the session, please register usingthis link. About ONWARD MedicalONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted...
Nasdaq GlobeNewswire
11/06/2025

Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational…

Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025Halle (Saale) / Munich, Germany, June 11 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2025 and...
Nasdaq GlobeNewswire
11/06/2025

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel…

Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June10, 2025(GLOBE NEWSWIRE) -- Philochem AG ("Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement...
Nasdaq GlobeNewswire
10/06/2025

Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of…

According to DelveInsight, there were approximately 207,000 prevalent GHD cases across the 7MM in 2024, with around 165,000 diagnosed. This number is projected to increase by 2034. The United States accounted for the largest share of diagnosed prevalent cases in 2024, with roughly 70,000 cases—a figure expected to grow over the 2025–2034 forecast period. According to DelveInsight, there were approximately207,000prevalent GHD cases across the 7MM in 2024, with around165,000diagnosed...
PR Newswire
10/06/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, June10, 2025(GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
10/06/2025

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of…

Daix (France), New York City (New York, United States), June 10, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company’s Annual General Meeting...
Nasdaq GlobeNewswire
10/06/2025

IV Therapy & Vein Access: Innovations Driving the Global Healthcare Market

This report provides an in-depth analysis of the global IV therapy and venous access market, covering applications across various healthcare settings. It studies IV solutions, infusion pumps and venous access devices, along with the current market trends, regulations, technological advancements and regional insights. Key innovations include AI-driven ultrasound for vein access and robotic-assisted catheter placement. It also offers market projections, share analysis and emerging developments…
PR Newswire
10/06/2025

SIFI merges into Faes Farma to become its ophthalmic franchise and expand…

SIFI will enable Faes Farma to offer one of the most comprehensive ophthalmology portfolios in the industry, with a complementary geographic presence. The integration of SIFI and Laboratorios Edol, a leading Portuguese pharmaceutical recently acquired by Faes Farma, positions ophthalmology as a pivotal area for the combined entity (the "Group"), representing approximately 20% of its pro-forma revenue, and allows for further portfolio synergies. SIFI will enable Faes Farma to offer one…
PR Newswire
10/06/2025

Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution

Safe Group announces FDA 510(k) clearance for SpineUp's Frida solutionFleurieux-sur-l’Arbresle-France - June 5, 2025 at 6 p.m.Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing...
Nasdaq GlobeNewswire
10/06/2025

Smart Healthcare Is Taking Over. Here's Where the Money's Headed

McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030. McKinsey's Global Instituteestimates Gen AI could unlock$60–110 billionin annual value across pharma and medical products alone.Statistanow projects the global AI healthcare market will soar from$11 billionto $188 billionby 2030. Avant...
PR Newswire
10/06/2025

Transactions under Novonesis’ share buyback program

Please read the announcement in PDF Attachment 2025_29_Share_buyback_program
Nasdaq GlobeNewswire
10/06/2025

Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR |…

Browse in-depth TOC on "Exosome Research Market" Browse in-depth TOC on "Exosome Research Market" 391 - Tables 52 - Figures 324 - Pages By offering,in 2024, the kits and reagents sector emerged as the dominant market segment within the exosome research market, commanding the largest share. This growth can be attributed primarily to the escalating demand for advanced diagnostic solutions aimed at addressing chronic diseases such as cancer, neurodegenerative disorders like...
PR Newswire
10/06/2025
Altri  Comunicati